16/07/2010Telstar strengthens its presence in Latin America and opens a branch in Mexico

• Telstar is one of the ten major international manufacturers of equipment for the pharmaceutical industry

• Telstar is the only company worldwide to offer integrated process solutions with its own technologies for the pharmaceutical and biotechnology industry

Telstar has a direct presence for the first time in Latin America with the opening of a branch of its own in Mexico which will offer direct servicing of engineering and integrated process equipment to the pharmaceutical and biotechnology companies in this market.

After 18 years of activity in Latin America, with a strong presence in Argentina, Cuba, Uruguay, Paraguay, Brazil and Mexico, Telstar has decided to strengthen its presence in Mexico by setting up a new branch with its own professional team to meet the specific needs of this market, which has high growth potential.

Telstar is the leading supplier of process equipment for the pharmaceutical industry in Spain, one of ten major equipment manufacturers for this sector in the international market and the only one with the ability to offer integrated solutions in the process field for the pharmaceutical industry with its own technologies of sterilisation, lyophilisation, containment and clean air. Furthermore it is one of the few companies in the world that can supply complete laboratories for the manufacture of medicines, including critical equipment.

The opening of Telstar's new office in Mexico forms part of the international expansion policy that Telstar has been developing in recent years.

A growing market

Mexico has high growth potential. This market is today one of the seven countries with emerging economies which is growing the fastest. After Brazil, Mexico is considered to be one of the main markets for healthcare products in the world and it is the second most important market in Latin America. This market currently occupies position number 11 in the global pharmaceutical industry market by volume of sales with estimated average growth of 6%.